MiMedx Group Inc (MDXG) Releases Earnings Results, Misses Expectations By $-0.02 EPS

MiMedx Group Inc (MDXG) reported quarterly earnings results on Tuesday, Jul-26-2016. The company reported $0.05 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $0.07. The company posted revenue of $57.34 million in the period, compared to analysts expectations of $56.20 million. The company’s revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.

MiMedx Group Inc opened for trading at $7.68 and hit $7.88 on the upside on Wednesday, eventually ending the session at $7.85, with a gain of 2.08% or 0.16 points. The heightened volatility saw the trading volume jump to 7,75,644 shares. Company has a market cap of $860 M.

In a different news, on Jun 17, 2016, William Charles Taylor (President and COO) sold 24,333 shares at $7.52 per share price. According to the SEC, on May 23, 2016, Parker H Petit (CEO) purchased 20,000 shares at $6.99 per share price. On Nov 16, 2015, Charles Robert Evans (director) purchased 10,000 shares at $7.84 per share price, according to the Form-4 filing with the securities and exchange commission.

MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.

MiMedx Group Inc

Leave a Reply

MiMedx Group Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on MiMedx Group Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.